COPENHAGEN (Reuters) – Novo Nordisk’s head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.
“I never commit to timelines but I would be very comfortable to say at the very least within this decade,” Martin Holst Lange said in an interview.
(Reporting by Reporting by Maggie Fick and Jacob Gronholt-Pedersen, writing by Louise Rasmussen, editing by Terje Solsvik)
